Kamada (KMDA) Reports Q2 Loss Per Share of 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Kamada Reports Second Quarter 2015 Financial Results
July 30, 2015 7:00 AM EDTConference call begins today at 8:30 a.m. Eastern time
NESS ZIONA, Israel--(BUSINESS WIRE)-- Kamada Ltd. (NASDAQ: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and six months ended June 30, 2015.
Financial highlights of the 2015 second quarter included:
Total revenues of $19.2 million compared with $15.8 million for the second quarter of 2014; Gross profit of $3.6 million compared with a gross loss of $0.10 million in the year-ago second quarter; and... More


